Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma
Public ClinicalTrials.gov record NCT00722137. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Open-Label, Multicenter Phase 3 Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone (VcR-CAP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Patients With Newly Diagnosed Mantle Cell Lymphoma Who Are Not Eligible for a Bone Marrow Transplant
Study identification
- NCT ID
- NCT00722137
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Millennium Pharmaceuticals, Inc.
- Industry
- Enrollment
- 487 participants
Conditions and interventions
Conditions
Interventions
- Rituximab 375 mg/m^2 Drug
- Cyclophosphamide 750 mg/m^2 Drug
- Doxorubicin 50 mg/m^2 Drug
- VELCADE 1.3 mg/m^2 Drug
- Prednisone 100 mg/m^2 Drug
- Vincristine 1.4 mg/m^2 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 30, 2008
- Primary completion
- Dec 31, 2013
- Completion
- Jun 16, 2017
- Last update posted
- Jul 11, 2018
2008 – 2017
United States locations
- U.S. sites
- 9
- U.S. states
- 9
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| St. Francis Hosptial and Medical Center | Hartford | Connecticut | 06105 | — |
| Center for Cancer Care at Goshen Hospital | Goshen | Indiana | 46526 | — |
| Sinai Hospital | Baltimore | Maryland | 21215 | — |
| Capitol Comp. Cancer Center | Jefferson City | Missouri | 65109 | — |
| Nebraska Cancer Specialists | Omaha | Nebraska | 68114 | — |
| Hematology-Oncology Associates of Northern NJ | Morristown | New Jersey | 07960 | — |
| Legacy Pharma Research | Bismarck | North Dakota | 58501 | — |
| Division of Hematology and Oncology Vanderbilt University | Nashville | Tennessee | 37232 | — |
| Cancer Outreach Associates, PC | Abingdon | Virginia | 24211 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 141 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00722137, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 11, 2018 · Synced Jun 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00722137 live on ClinicalTrials.gov.